Remove Marketing Remove Pharmaceuticals Remove Research Remove White Paper
article thumbnail

Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent Analysis

The Pharma Data

Teva Pharmaceutical Industries Ltd. billion across its major markets in 2020 alone. These major markets represented 75% of Teva’s revenues in 2020. Across 9 major markets in Europe, Teva saved healthcare systems $9.6 Teva saved the United States $28.8 billion in 2020, $4.2 jobs and contributed $15.7 billion in 2020.

article thumbnail

Informed Design of Bioanalytical PCR Assay Testing Parameters

PPD

There are over 2,000 CGTs currently being evaluated in clinical trials, with more than 200 in Phase III and 10-20 per year estimated to come to market by 2025. Emerging areas of pharmaceutical research not only bring novel opportunities but also new regulatory guidance.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Navigating the Global Clinical Landscape: CTA or IND for Your First-in-Human Study?

Conversations in Drug Development Trends

When conducting first-in-human (FIH) clinical trials, small to midsize pharmaceutical and biotechnology companies are faced with several crucial choices that can shape the trajectory of their drug development pathway. For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.

article thumbnail

Patient-Centric Strategies for Successful Oncology Trials

PPD

For pharmaceutical innovators and drug developers working to bring oncology therapies to market, patients are the “why” behind it all. Researchers often employ cell therapy studies for oncology indications, and the U.S. For many patients, involvement in oncology clinical trials represents a last hope for an effective therapy.

Trials 64
article thumbnail

Compliant Science: The Critical Role of Compliance for Medical Affairs

H1 Blog

Since KOLs play such a critical role, engaging with the right KOLs is a key strategy for pharmaceutical companies to stay ahead of the game. Compliance ensures that interactions between pharmaceutical companies and KOLs are transparent, fair, and free from any undue influence.

article thumbnail

Scopus BioPharma Announces Appointment of Additional Directors

The Pharma Data

Our new directors are well-recognized for their leadership and accomplishments in the biopharmaceutical, biotechnology and pharmaceutical industries, as well as in public capital markets and corporate governance.” ” The new directors are: Raphael (“Rafi”) Hofstein, Ph.D. Dr. Hofstein received his B.Sc.

article thumbnail

The Changing R&D Landscape – Contract Pharma

The Pharma Data

The pharmaceutical product landscape is rapidly and fundamentally changing with profound impact on research and development strategy and technology needs. Emerging Technology Needs and Value Proposition for Strategic Partnerships with Contract Development and Manufacturing Organizations (CDMOs).